173 Episodo

  1. Ep135: John Maraganore on Developing a New Class of Medicines

    Publicado: 8/5/2023

  2. Ep134: Emile Nuwaysir on In Vivo Gene Editing Therapies

    Publicado: 24/4/2023

  3. Ep133: Catherine Stehman-Breen on Epigenetic Editing Therapies

    Publicado: 12/4/2023

  4. Ep132: Eric Dobmeier on Treating Kidney Disease

    Publicado: 28/3/2023

  5. Ep131: Ryan Watts on Neuroscience Drug R&D

    Publicado: 14/3/2023

  6. Ep130: David Hallal on a Life in Biotech & the Cell Therapy Wave

    Publicado: 28/2/2023

  7. Ep129: Joanne Smith-Farrell on Engineered B-Cell Therapies

    Publicado: 14/2/2023

  8. Ep128: Rick Berke on Building a Biotech Journalism Outlet to Last

    Publicado: 1/2/2023

  9. Ep127: Jeb Keiper on Computational Drug Discovery

    Publicado: 20/1/2023

  10. Ep126: DA Wallach on Becoming a Biotech VC

    Publicado: 3/1/2023

  11. Ep125: Barry Greene on a New Drug for Depression

    Publicado: 19/12/2022

  12. Ep124: Shehnaaz Suliman on Delivery of Genetic Medicines

    Publicado: 8/11/2022

  13. Ep123: Tariq Kassum on Single-Cell Analysis for Drug Discovery

    Publicado: 27/10/2022

  14. Ep122: Aetna Wun Trombley on Extracellular Protein Degraders

    Publicado: 11/10/2022

  15. Ep121: Samantha Truex on Going Upstream Against Severe Asthma

    Publicado: 26/9/2022

  16. Ep120: Tim Lu on Gene Circuits for Cell Therapy

    Publicado: 7/9/2022

  17. Ep119: Jo Viney on Discovering Treatments for Autoimmune Disease

    Publicado: 22/8/2022

  18. Ep118: Ivan Liachko on Assembling Accurate Genomes and Interactomes

    Publicado: 8/8/2022

  19. Ep117: Dr. Sanduk Ruit on Restoring Eyesight in the Developing World

    Publicado: 11/7/2022

  20. Ep116: Ivana Magovcevic-Liebisch on Precision Neuroscience

    Publicado: 22/6/2022

3 / 9

"The Long Run" Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.

Visit the podcast's native language site